Several studies have also shown that other SGLT2 inhibitors such as ipragliflozin and luseogliflozin, alleviate hepatic steatosis and steatohepatitis in rodents with obesity and T2DM [38, 39]. This evidence concerns the gene SLC5A2 and fatty liver disease.